Showing results (71-80 of 100) with videos related to

Sort By:
Pageof 10
The Annals of Pharmacotherapy|July 3, 2008
Effects of AGTR1 A1166C gene polymorphism in patients with heart failure treated with candesartanSimon de Denus, Marcin Zakrzewski-Jakubiak, Marie-Pierre Dubé, et al.
Pharmacogenomics|June 12, 2023
Pharmacogenomic markers of metoprolol and α-OH-metoprolol concentrations: a genome-wide association studyJean Laverdière, Maxime Meloche, Sylvie Provost, et al.
International Journal of Cardiology|February 2, 2024
High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCATJoão Pedro Ferreira, Brian L Claggett, Jiankang Liu, et al.
JACC. Heart Failure|August 18, 2020
Care Gaps in Adherence to Heart Failure Guidelines: Clinical Inertia or Physiological Limitations?Marilyne Jarjour, Christine Henri, Simon de Denus, et al.
Clinical and Translational Science|March 2, 2023
Females present higher dose-adjusted drug concentrations of metoprolol and allopurinol/oxypurinol than malesJessica Hindi, Marc-Olivier Pilon, Maxime Meloche, et al.
European Journal of Heart Failure|April 3, 2020
Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trialSimon de Denus, Grégoire Leclair, Marie-Pierre Dubé, et al.
Circulation. Heart Failure|December 21, 2018
Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection FractionPeder L Myhre, Eileen O'Meara, Brian L Claggett, et al.
ESC Heart Failure|September 2, 2020
A genetic association study of heart failure: more evidence for the role of BAG3 in idiopathic dilated cardiomyopathySimon de Denus, Fannie Mottet, Sandra Korol, et al.
Journal of Personalized Medicine|June 27, 2024
A Genome-Wide Association Study of Oxypurinol Concentrations in Patients Treated with AllopurinolMaxime Meloche, Marc-Olivier Pilon, Sylvie Provost, et al.
Pageof 10